Atenolol-associated cholestasis.
Atenolol, a beta 1-selective beta-adrenergic receptor-blocking agent, is frequently used for the treatment of hypertension and angina pectoris. We report our experience with a patient who developed cholestatic hepatitis related to the initiation of therapy with atenolol with prompt resolution of symptoms and biochemical abnormalities upon discontinuation of this medication. A review of the literature failed to demonstrate any prior report of atenolol-associated hepatic injury. Although rare, because of the common use of atenolol, clinicians should be aware of this potential adverse effect.
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.
M S
MS
Schwartz
M S
MS
Frank
A
A
Yanoff
R
R
Morecki
D000368:Aged; D001262:Atenolol / Q000009:adverse effects*; D002779:Cholestasis / Q000139:chemically induced*; D006801:Humans; D008297:Male
D001262:Atenolol